Effect of high protein-low carbohydrate weight loss diet with fennel supplement in women with polycystic ovary syndrome.

Study of the effect of high protein-low carbohydrate weight loss diet with fennel supplement on androgens and anthropometric indices in overweight and obese women with polycystic ovary syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120913010826N28

Enrollment

Registered

2018-04-07

Start date

2017-10-22

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group1: Prescribe high protein- low carbohydrate weight loss diet with 2 fennel capsule per day. Intervention 2: Intervention group 2: prescribe high protein-low carbohydr

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: polycystic ovary syndrome based on the Rotterdam criteria, at least two criteria of the three following criteria: 1) anovulation or oligo- ovulation or menstrual cycle less than 6 times in 12 months. 2) Clinical or biochemical increase in androgens, including the presence of acne, hirsutism, alopecia or serum levels of androgens . 3) Polycystic view with 12 or more follicles in each ovary with a diameter of between 3-2Myly meters or ovarian volume increased more than 11 cm overweight or obese (BMI greater than or equal to 25) aged 18-45 years willing to participate in this study

Exclusion criteria

Exclusion criteria: The other causes of hyperandrogenism? Congenital adrenal hyperplasia? Cushing, hypothyroidism, hyperprolactinemia, and Androgen-secreting tumors and those with hirsutism, acne or severe hair loss Allergy to anise or any of its components pregnant women and people who desire to pregnancy allergic asthma seizures liver and renal (urea and creatinine above the normal range) disease cancer

Design outcomes

Primary

Measure	Time frame
Total Testosterone. Timepoint: befor and after 12 weeks treatment. Method of measurement: Using ELISA.;SHBG(Sex hormone-binding globulin). Timepoint: befor and after 12 weeks treatment. Method of measurement: Using ELISA.;Weight. Timepoint: befor and after 12 weeks treatment. Method of measurement: Scale.;Waist circumference. Timepoint: befor and after 12 weeks treatment. Method of measurement: Meter.;Hip circumfernce. Timepoint: befor and after 12 weeks treatment. Method of measurement: Meter.	—

Measure

Time frame

Total Testosterone. Timepoint: befor and after 12 weeks treatment. Method of measurement: Using ELISA.;SHBG(Sex hormone-binding globulin). Timepoint: befor and after 12 weeks treatment. Method of measurement: Using ELISA.;Weight. Timepoint: befor and after 12 weeks treatment. Method of measurement: Scale.;Waist circumference. Timepoint: befor and after 12 weeks treatment. Method of measurement: Meter.;Hip circumfernce. Timepoint: befor and after 12 weeks treatment. Method of measurement: Meter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Hosseini Marnani

??????? ???? ????? ???

Elham_Hosseini1993@yahoo.com+98 35 3820 9100

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026